

**Anti-FGFR3 / CD333 Reference Antibody (vofatamab)
Recombinant Antibody
Catalog # APR10112****Specification**

Anti-FGFR3 / CD333 Reference Antibody (vofatamab) - Product Information

Application	FC, Kinetics, Animal Model
Primary Accession	P22607
Reactivity	Human, Mouse
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	146.44 KDa

Anti-FGFR3 / CD333 Reference Antibody (vofatamab) - Additional Information**Target/Specificity**
FGFR3 / CD333**Endotoxin**
< 0.001EU/ µg,determined by LAL method.**Conjugation**
Unconjugated**Expression system**
CHO Cell**Format**
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-FGFR3 / CD333 Reference Antibody (vofatamab) - Protein Information****Name** FGFR3**Synonyms** JTK4**Function**
Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineralization by osteoblasts. Promotes apoptosis in chondrocytes, but can also promote cancer cell proliferation. Required for normal development of the inner ear. Phosphorylates PLCG1, CBL and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling

pathway, as well as of the AKT1 signaling pathway. Plays a role in the regulation of vitamin D metabolism. Mutations that lead to constitutive kinase activation or impair normal FGFR3 maturation, internalization and degradation lead to aberrant signaling. Over-expressed or constitutively activated FGFR3 promotes activation of PTPN11/SHP2, STAT1, STAT5A and STAT5B. Secreted isoform 3 retains its capacity to bind FGF1 and FGF2 and hence may interfere with FGF signaling.

Cellular Location

[Isoform 1]: Cell membrane; Single-pass type I membrane protein. Cytoplasmic vesicle. Endoplasmic reticulum. Note=The activated receptor is rapidly internalized and degraded. Detected in intracellular vesicles after internalization of the autophosphorylated receptor [Isoform 3]: Secreted.

Tissue Location


Expressed in brain, kidney and testis. Very low or no expression in spleen, heart, and muscle. In 20- to 22-week old fetuses it is expressed at high level in kidney, lung, small intestine and brain, and to a lower degree in spleen, liver, and muscle. Isoform 2 is detected in epithelial cells. Isoform 1 is not detected in epithelial cells. Isoform 1 and isoform 2 are detected in fibroblastic cells.

Anti-FGFR3 / CD333 Reference Antibody (vofatamab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


Anti-FGFR3 / CD333 Reference Antibody (vofatamab) - Images



Anti-FGFR3 / CD333 Reference Antibody (vofatamab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-FGFR3 / CD333 Reference Antibody (vofatamab) is more than 100% ,determined by SEC-HPLC.



Immobilized human FGFR3IIIb His at 2 µg/mL can bind Anti-FGFR3 / CD333 Reference Antibody (vofatamab) □ EC50=0.00402 µg/mL